Biodegradable Cationic Lipids for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as mRNA, face challenges in achieving effective in vivo delivery while maintaining a favorable toxicity profile.
Innovation Solution
Development of a novel class of biodegradable lipid compounds, specifically cationic lipids, which are used to formulate lipid nanoparticles like liposomes for encapsulating nucleic acids, enhancing delivery efficacy while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid formulations are used for nucleic acid delivery, then delivery efficiency can be achieved, but toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of lipid compounds by introducing biodegradable linkages (e.g., ester bonds, amide bonds) and adjusting hydrophobic/hydrophilic ratios. These parameter changes enable the lipids to maintain effectiveness for nucleic acid complexation and delivery while being metabolized into non-toxic products, thus reducing toxicity without sacrificing delivery efficiency
Solution Approach 2:
The patent creates composite lipid formulations combining biodegradable cationic lipids with neutral or anionic lipids. This composite approach allows the cationic component to provide effective nucleic acid binding and cellular uptake, while the biodegradable nature and complementary lipids reduce overall toxicity and improve biocompatibility
2Object-affected harmful factors
If biodegradable lipid compounds are used, then toxicity is reduced, but delivery efficacy may be compromised
Solution Approach 1:
The patent designs lipids with dynamic properties that change in response to biological environments. The biodegradable lipids remain stable during storage and initial delivery, then progressively degrade after cellular uptake to release the nucleic acid payload. This temporal dynamic behavior ensures both effective delivery and reduced long-term toxicity
Solution Approach 2:
The biodegradable lipid acts as an intermediary carrier that temporarily holds and transports the nucleic acid to the target site. The lipid's controlled degradation serves as a mediator between delivery and elimination, allowing the system to achieve therapeutic effect while the degradation products are safely metabolized, thus maintaining delivery efficacy without compromising safety
Data Source
AI summary
The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof:Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.